New pharmacotherapy options for noninfectious posterior uveitis.
Int Ophthalmol
; 41(6): 2265-2281, 2021 Jun.
Article
in En
| MEDLINE
| ID: mdl-33634341
ABSTRACT
INTRODUCTION:
Noninfectious inflammation of the posterior eye segment represents an important cause of visual impairment. It often affects relatively young people and causes a significant personal and social impact. Although steroids and nonbiologic- Disease-Modifying Antirheumatic Drugs (nbDMARDs) are effective both in acute and long- lasting diseases, however they are increasingly being replaced by biologic (DMARDs). bDMARD. This article therefore aims to identify recent advances in the therapy of noninfectious posterior segment uveitis.METHODS:
A Medline-search was conducted using the terms nbDMARD, bDMARD, posterior uveitis, intermediate uveitis, treatment, corticosteroid. In addition, clinical studies were included as registered at ClinicalTrials.gov.RESULTS:
Currently two major lines of treatments can be identified (1) the intraocular application of anti-inflammatory agents and (2) the introduction of new agents, e.g., (bDMARDs) and small-molecule-inhibitors. Whereas intravitreal treatments have the advantage to avoid systemic side effects, new systemic agents are progressively earning credit on the basis of their therapeutic effects.CONCLUSION:
Even when current treatment strategies are still hampered by the limited number of randomized controlled trials, promising progress and continuous efforts are seen.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Uveitis
/
Uveitis, Intermediate
/
Uveitis, Posterior
/
Antirheumatic Agents
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
/
Systematic_reviews
Limits:
Adolescent
/
Humans
Language:
En
Journal:
Int Ophthalmol
Year:
2021
Document type:
Article
Affiliation country:
Alemania